Xenon Pharmaceuticals Financials
| XENE Stock | USD 35.34 0.49 1.41% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.0113 | 0.0119 |
|
| |||||
| Current Ratio | 13.26 | 17.8495 |
|
|
Investors should never underestimate Xenon Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Xenon Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Xenon Pharmaceuticals.
Net Income |
|
Xenon | Select Account or Indicator |
Understanding current and past Xenon Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Xenon Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Xenon Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the presentation of Xenon Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Xenon Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Xenon Pharmaceuticals' management manipulating its earnings.
Xenon Pharmaceuticals Stock Summary
Xenon Pharmaceuticals competes with Nuvalent, Arcellx, Vaxcyte, Viridian Therapeutics, and Crinetics Pharmaceuticals. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Xenon Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | CA98420N1050 |
| CUSIP | 98420N105 |
| Location | British Columbia; Canada |
| Business Address | 200-3650 Gilmore Way, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.xenon-pharma.com |
| Phone | 604 484 3300 |
| Currency | USD - US Dollar |
Xenon Pharmaceuticals Key Financial Ratios
| Return On Equity | -0.28 | ||||
| Price To Sales | 181.44 X | ||||
| Gross Profit | (210.39 M) | ||||
| EBITDA | (279.3 M) | ||||
| Net Income | (234.33 M) |
Xenon Pharmaceuticals Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 189.2M | 572.0M | 754.1M | 964.8M | 798.1M | 838.0M | |
| Other Current Liab | 7.8M | 9.9M | 13.7M | 17.4M | 23.5M | 24.6M | |
| Net Debt | (41.7M) | (167.4M) | (46.8M) | (137.7M) | (133.7M) | (127.0M) | |
| Retained Earnings | (278.5M) | (357.4M) | (482.7M) | (665.1M) | (899.5M) | (854.5M) | |
| Accounts Payable | 3.0M | 3.8M | 8.5M | 8.6M | 5.1M | 3.2M | |
| Cash | 45.0M | 175.7M | 57.2M | 148.6M | 142.7M | 78.5M | |
| Net Receivables | 1.8M | 2.8M | 986K | 874K | 1.5M | 929.5K | |
| Other Current Assets | 3.0M | 4.5M | 7.2M | 6.0M | 6.9M | 7.2M | |
| Total Liab | 17.8M | 22.0M | 32.6M | 36.9M | 43.2M | 28.8M | |
| Total Current Assets | 181.8M | 559.0M | 600.3M | 645.0M | 635.3M | 667.0M | |
| Common Stock | 397.7M | 783.2M | 1.1B | 1.4B | 1.5B | 1.5B | |
| Net Tangible Assets | 84.2M | 163.6M | 542.3M | 721.5M | 829.7M | 871.2M | |
| Other Assets | 523K | 465K | 143.7M | 306.2M | 135.0M | 141.7M | |
| Capital Surpluse | 40.6M | 45.4M | 117.5M | 142.1M | 163.4M | 171.6M | |
| Net Invested Capital | 163.6M | 542.3M | 721.5M | 927.9M | 754.9M | 462.5M |
Xenon Pharmaceuticals Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 1.4M | 484K | 1.0M | 5.5M | 6.3M | 6.7M | |
| Gross Profit | 32.2M | 18.4M | 9.4M | (167.5M) | (150.8M) | (143.2M) | |
| Operating Income | (31.3M) | (79.0M) | (129.1M) | (214.1M) | (279.3M) | (265.3M) | |
| Ebit | (31.3M) | (79.0M) | (129.1M) | (214.1M) | (192.6M) | (183.0M) | |
| Research Development | 50.5M | 75.5M | 105.8M | 167.5M | 210.4M | 220.9M | |
| Ebitda | (30.7M) | (78.1M) | (127.5M) | (210.5M) | (279.3M) | (265.3M) | |
| Income Before Tax | (29.1M) | (78.9M) | (125.3M) | (182.7M) | (238.4M) | (226.5M) | |
| Net Income | (28.8M) | (78.9M) | (125.4M) | (182.4M) | (234.3M) | (222.6M) | |
| Income Tax Expense | (257K) | (6K) | 118K | (292K) | 4.1M | 4.3M | |
| Cost Of Revenue | 50.5M | 75.5M | 105.8M | 167.5M | 192.6M | 202.3M | |
| Interest Income | 2.3M | 466K | 8.7M | 23.4M | 41.9M | 44.0M | |
| Net Interest Income | 1.8M | 466K | 8.7M | 23.4M | 41.9M | 44.0M | |
| Tax Provision | (257K) | (6K) | 118K | 1.1M | (4.1M) | (3.9M) |
Xenon Pharmaceuticals Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 20.3M | 130.7M | (118.4M) | 91.4M | (5.9M) | (5.6M) | |
| Free Cash Flow | (50.8M) | (71.6M) | (101.3M) | (150.9M) | (181.4M) | (172.3M) | |
| Depreciation | 644K | 906K | 1.6M | 3.5M | 2.6M | 2.7M | |
| Other Non Cash Items | 766K | 1.0M | 5.7M | (4.2M) | 11.1M | 11.6M | |
| Capital Expenditures | 2.6M | 2.1M | 2.9M | 5.6M | 3.1M | 1.7M | |
| Net Income | (28.8M) | (78.9M) | (125.4M) | (182.4M) | (234.3M) | (222.6M) | |
| End Period Cash Flow | 45.0M | 175.7M | 57.2M | 148.6M | 142.7M | 74.0M | |
| Investments | (14.2M) | (244.7M) | (293.1M) | 108.2M | 165M | 173.3M | |
| Change To Netincome | 2.5M | 5.9M | 11.1M | 23.1M | 26.5M | 27.8M | |
| Change To Inventory | (783K) | (4.5M) | (2.0M) | (3.0M) | (2.7M) | (2.5M) | |
| Change Receivables | (653K) | (1.0M) | (459K) | 1.8M | 2.0M | 2.1M |
Xenon Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Xenon Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Xenon Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Xenon Pharmaceuticals competition to find correlations between indicators driving Xenon Pharmaceuticals's intrinsic value. More Info.Xenon Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Xenon Pharmaceuticals' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Xenon Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Xenon Pharmaceuticals Systematic Risk
Xenon Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Xenon Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Xenon Pharmaceuticals correlated with the market. If Beta is less than 0 Xenon Pharmaceuticals generally moves in the opposite direction as compared to the market. If Xenon Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Xenon Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Xenon Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Xenon Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Xenon Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Xenon Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Xenon Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Xenon Pharmaceuticals March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Xenon Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Xenon Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Xenon Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Xenon Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Xenon Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 9.96 | |||
| Value At Risk | (3.37) | |||
| Potential Upside | 3.15 |
Complementary Tools for Xenon Stock analysis
When running Xenon Pharmaceuticals' price analysis, check to measure Xenon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xenon Pharmaceuticals is operating at the current time. Most of Xenon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xenon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xenon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xenon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |